GlassScriptPhysician profile
Ilana L Stone
NPI 1689870198
$5,929.77
in general payments reported to CMS, 2019-2025
27 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $648 · 2023: $1,440 · 2024: $868 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,109.15 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,106.48 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $653.05 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $574.64 | 2021-2025 | Andembry, Haegarda, Hizentra |
| Genzyme Corporation | $403.13 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $386.19 | 2022-2025 | Takhzyro, Cuvitru, Eohilia |
| Ars Pharmaceuticals Operations, INC. | $232.04 | 2025 | Neffy |
| Genentech USA, INC. | $190.41 | 2022-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $169.83 | 2021-2025 | |
| Amgen INC. | $149.97 | 2022-2023 | Tezspire |
| Optinose US, INC. | $138.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.76 | 2021 | |
| Phathom Pharmaceuticals, INC. | $120.99 | 2024 | Voquezna |
| Octapharma USA, INC. | $99.45 | 2025 | Cutaquig |
| Biocryst US Sales Co., LLC | $77.42 | 2024-2025 | Orladeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $70.79 | 2021-2025 | Ruconest |
| Grifols USA, LLC | $46.35 | 2023 | Xembify |
| Lilly USA, LLC | $40.10 | 2025 | Ebglyss |
| Abbvie INC. | $39.01 | 2022-2024 | |
| Kaleo, INC. | $35.42 | 2021 | |
| Pfizer INC. | $33.70 | 2023 | |
| Insmed, INC. | $23.26 | 2025 | Brinsupri |
| Teva Pharmaceuticals USA, INC. | $22.81 | 2021 | |
| Aimmune Therapeutics, INC. | $19.66 | 2021 | |
| Incyte Corporation | $17.71 | 2022 | |
| Merck Sharp & Dohme LLC | $17.51 | 2023 | |
| Gc Biopharma USA, INC. | $14.01 | 2025 | Alyglo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilana Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.